Gene and cell therapy group Oxford Biomedica has signed a one-year clinical and commercial supply agreement with AstraZeneca for the manufacture of a Covid-19 vaccine candidate. The agreement relates to the GMP manufacture of the adenovirus vector based Covid-19 vaccine candidate, AZD1222, which recently entered clinical trials at… Read More
The global biotech company announced the launch of its new cell-based vaccine platform targeting severe acute respiratory syndrome SARS-CoV-2, as well as other viral diseases such as Zika, West Nile Virus, Yellow Fever, Dengue Fever, MERS, HCV and Cytomegalovirus infection (CMV). Orgenesis said it has been “working aggressively”… Read More
18 May, 2020 The research-driven pharmaceutical company said the new acquisition provides assets targeting the tumour stroma and myeloid cells. Boehringer Ingelheim also announced it is collaborating with CDR-Life to develop antibody fragment-based therapeutics for geographic atrophy, a leading cause of blindness. The first programme, now in late… Read More
The Israel based developer of nearly painless intradermal delivery solutions for vaccines and drugs said it is joining forces with leading vaccine and immunotherapy companies worldwide to share its proprietary MicronJet microneedle device. According to NanoPass, the aim is to enable the development of a safe, effective and… Read More
The CRISPR revolution arrives in immuno-oncology By Helen Stewart-Miller and Thomas Hope Volume 21 Issue 2 – Spring 2020 CRISPR-cas9 technology is having an exciting impact on drug discovery as a whole, but more specifically CRISPR presents enormous opportunities in targeted screening for immuno-oncology research. Clustered… Read More
Meeting analytical challenges in a brave new world of next generation biotherapeutics By Mani Krishnan and Susan Darling Volume 21 Issue 2 – Spring 2020 The need for innovative advanced analytical tools to accelerate the development of immunotherapies and other complex biologics that may one day cure genetic… Read More
ADCs and solid tumours – The payload revolution that drives therapeutic opportunities in unmet need By Dr Jenny Thirlway Volume 21 Issue 2 – Spring 2020 The fight against cancer is ongoing. Despite progress in many indications, mortality rates for some of the most difficult to treat… Read More
Antimicrobial resistance threatens to undermine our healthcare system By Dr Peter Jackson Volume 21 Issue 2 – Spring 2020 The immediate global challenge to human health and our economic stability due to coronavirus acts as a stark reminder that infectious disease preparedness cannot be ignored. Read More
Reprogramming the stem cell for a new generation of cures By Dr Alex Davenport, Dr Tonya Frolov and Dr Mark Kotter Volume 21 Issue 2 – Spring 2020 The development of new and effective treatments with the potential to cure, or at the very least ease patient suffering,… Read More
Drug development 2.0 – The partnership model in practice By Dr Brian Sheehan and Marco Cerato Over the last decade there has been a fundamental shift in the way in which drugs are developed and brought to market. Some years ago, the industry started to see profits falling… Read More
Cryo-EM accelerates drug discovery by delivering previously intractable structural insights By Hans Raaijmakers, et al. Cryo-electron microscopy (cryo-EM), a powerful biophysical technique that can analyse molecular assemblies, is changing the paradigm in structure-based drug design. As targets become more challenging, solving structures of drug target molecules… Read More
Harnessing the modified proteome for increased diagnostic power By Dr David Bramwell, Dr Steven Laval and Dr Jane McLeod Relevant biomarkers are vitally important in personalised medicine, guiding patient matching to specific therapies for earlier, easier and more effective disease identification and treatment. Here we trace… Read More
Unlocking the potential of Extracellular Vesicles: from single molecules to novel therapeutics By Dr Anna Caballe and Dr Katarzyna Ginda-Makela As part of normal homeostasis, cells release different types of small-sized membrane vesicles to traffic analytes across membranes, communicate with other cells and remove unwanted cell content. These… Read More
By Dr Steve Arlington and John Wise As part of its mission to help members anticipate and prepare for changes in the pharmaceutical industry, The Pistoia Alliance has developed a research paper which sets out to consider what the life science, biopharma R&D and healthcare ecosystem might… Read More
By Dr Alexander C. Maue It has become quite evident that the microbiome has the potential to impact drug discovery in vital ways. In addition to impacting study reproducibility and variability, the microbiome may influence drug efficacy or serve as a therapeutic agent. To… Read More
2030 Life Sciences and Health in the Digital Age (Part 1) By Dr Steve Arlington and John Wise One of the key ways in which The Pistoia Alliance works with its members is to help them not just deal with the problems of today, but also to… Read More